The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer
Open accessAbstract
A series of three dose escalating studies were conducted to investigate the ability of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate, to cause maximum suppression of testosterone synthesis when delivered to castrate and noncastrate males with prostate cancer. Study A was a single dose study in castrate males. Study B was a single dose study in noncastrate males and study C was a multiple dose study in noncastrate males. The drug was given orally in a once-daily dose and blood samples taken to assess pharmacokinetic (PK) parameters and hormone levels in all patients. The study drug was well tolerated with some variability in PKs. Suppression of testosterone levels to <0.14 nmol l(-1) was seen in four out of six castrate males treated with a single dose of 500 mg. At 800 mg given days 1-12 in noncastrate males, target suppression was achieved in three out of three patients, but a two- to three-fold increase of Luteinising Hormone (LH) levels in two out of three patients overcame suppression within 3 days. All patients in the multiple dose study developed an abnormal response to a short Synacthen test by day 11, although baseline cortisol levels remained normal. This is the first report of the use of a specific 17alpha-hydroxylase/(17,20)-lyase inhibitor in humans. Repeated treatment of men with intact gonadal function with abiraterone acetate at a dose of 800 mg can successfully suppress testosterone levels to the castrate range. However, this level of suppression may not be sustained in all patients due to compensatory hypersecretion of LH. The enhanced testosterone suppression achieved in castrate men merits further clinical study as a second-line hormonal treatment for prostate cancer. Adrenocortical suppression may necessitate concomitant administration of replacement glucocorticoid.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman and Gilman's The Pharmacological Basis of Therapeutics
Hastings, R. C. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540120077042 · Cited by 2,371
Williams Textbook of Endocrinology
Stoffer, S. S. (1999) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.281.9.851 · Cited by 1,253
Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer.
Linja, M. J., Savinainen, K., Saramäki, O. R., Tammela, T. L. J., Vessella, R. L., & Visakorpi, T. (2001) · PubMed · Cited by 774
Gregory, C. W., He, B., Johnson, R. T., Ford, O. H., Mohler, J. L., French, F. S., & Wilson, E. M. (2001) · PubMed · Cited by 708
Bubendorf, L., Kononen, J., Koivisto, P. A., Schraml, P., Moch, H., Gasser, T. C., Willi, N., Mihatsch, M. J., Sauter, G., & Kallioniemi, O. (1999) · PubMed · Cited by 594
A history of prostate cancer treatment.
Denmeade, S. R., & Isaacs, J. T. (2002) · Nature reviews. Cancer · doi:10.1038/nrc801 · Cited by 591
(2001) · PubMed · Cited by 500
Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes.
Loose, D. S., Kan, P. B., Hirst, M. A., Marcus, R. A., & Feldman, D. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110903 · Cited by 443
The Current State of Hormonal Therapy for Prostate Cancer
Hellerstedt, B. A., & Pienta, K. J. (2002) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.52.3.154 · Cited by 386
Potter, G. A., Barrie, S. E., Jarman, M., & Rowlands, M. G. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00013a022 · Cited by 379
Self-citationOral chemotherapy: rationale and future directions.
DeMario, M. D., & Ratain, M. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2557 · Cited by 293
Pharmacology of novel steroidal inhibitors of cytochrome P45017 (17α-hydroxylase/C17–20 lyase)
Barrie, S. E., Potter, G. A., Goddard, P. M., Haynes, B. P., Dowsett, M., & Jarman, M. (1994) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(94)90131-7 · Cited by 253
Self-citationRowlands, M., Barrie, S. E., Chan, F., Houghton, J., Jarman, M., McCague, R., & Potter, G. A. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00021a008 · Cited by 90
Self-citationAntiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long, B. J., Grigoryev, D. N., Nnane, I. P., Liu, Y., Ling, Y. Z., & Brodie, A. M. (2000) · PubMed · Cited by 69
Secondary hormonal therapies in the treatment of prostate cancer
Oh, W. K. (2002) · Urology · doi:10.1016/s0090-4295(02)01581-9 · Cited by 63
Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P45017α inhibitors
Barrie, S. E., Haynes, B. P., Potter, G. A., Chan, F. C. Y., Goddard, P. M., Dowsett, M., & Jarman, M. (1997) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(96)00225-7 · Cited by 37
Self-citationAminoglutethimide in Advanced Prostatic Carcinoma
Harnett, P. R., Raghavan, D., Caterson, I. D., Pearson, B., Watt, H., Teriana, N., Coates, A. S., & COOREY, G. J. (1987) · British Journal of Urology · doi:10.1111/j.1464-410x.1987.tb04641.x · Cited by 23
Klijn, J. G. M., de Voogt, H. J., Studer, U. E., Schröder, F. H., Sylvester, R. J., & Pauw, M. D. (1993) · Cancer · doi:10.1002/1097-0142(19931215)72:12+<3888::aid-cncr2820721726>3.0.co;2-b · Cited by 17
Effects of High-Dose Ketoconazole in Patients with Androgen-Independent Prostatic Cancer
Eichenberger, T., & Trachtenberg, J. (1988) · American Journal of Clinical Oncology · doi:10.1097/00000421-198801102-00025 · Cited by 15
Cited by
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704174 · Cited by 2,308
Fizazi, K., Scher, H. I., Molina, A., Logothetis, C. J., Chi, K. N., Jones, R. J., Staffurth, J. N., North, S., Vogelzang, N. J., Saad, F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70379-0 · Cited by 1,384
Self-citationThe insulin and insulin-like growth factor receptor family in neoplasia: an update
Pollak, M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3215 · Cited by 1,116
Metadata
- Authors
- O'Donnell, A., Judson, I., Dowsett, M., Raynaud, F., Dearnaley, D., Mason, M., Harland, S., Robbins, A., Halbert, G., Nutley, B., & Jarman, M.
- Venue
- British Journal of Cancer
- Published
- 2004-05-18
- Volume
- 90
- Issue
- 12
- Pages
- 2317-2325
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2171041379
- Cited by
- 382
- References
- 19
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.